Ovarian Clear Cell Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Ovarian Clear Cell Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors [Phase 1]
Phase 1 clinical trial evaluating IACS-6274 with or without Bevacizumab and Paclitaxel in adults with advanced solid tumors; the study is cu…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer [Phase 1]
Phase 1 clinical trial assessing different dosing amounts of the drug combination M1774 and ZEN-3694 for recurrent ovarian and endometrial c…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab in combination with bevacizumab, with or without the anti-CD40 agonist CDX-1140, for recur…
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]
Clinical trial update reporting results from a Phase 1/2 study of ruxolitinib phosphate in combination with paclitaxel and carboplatin for S…
-
CLINICAL_TRIALS trial_result · 2024-09-20Clinical Trial Update: Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) [Phase 2]
Phase 2 Imperial College London study evaluating dual mTORC1/2 inhibition in advanced or recurrent epithelial ovarian, fallopian tube, or pr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-11-06Clinical Trial Update: Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab, bevacizumab, and cyclophosphamide in recurrent ovarian, fallopian tube, or primary peritone…
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial update for cabozantinib-s-malate in recurrent or progressive ovarian, fallopian tube, or primary peritoneal cancer.
-
CLINICAL_TRIALS trial_result · 2019-09-17Clinical Trial Update: Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating elesclomol sodium with paclitaxel in patients with recurrent or persistent ovarian epithelial cancer, fallopian tub…
-
CLINICAL_TRIALS trial_result · 2017-07-21Clinical Trial Update: Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer [Phase 2]
Phase 2 trial evaluating sunitinib malate in persistent or recurrent clear cell ovarian cancer has completed with results posted.